Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1211.50 | +7.4% | 5.3M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.5t | $254.38 | +4.0% | 9.7M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $384.7b | $252.95 | +4.1% | 11.1M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $293.2b | $128.22 | +1.7% | 9.8M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $287.9b | $188.18 | +1.5% | 2.5M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $181.8b | $357.17 | +1.4% | 1.7M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $166.9b | $127.40 | +2.8% | 7.2M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $116.8b | $57.40 | +3.8% | 9.2M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $64.5b | $629.25 | +2.1% | 689.1K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $33.5b | $182.99 | +2.2% | 2.9M |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $32.0b | $261.00 | -0.0% | 2.2M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $24.7b | $55.59 | +2.9% | 4.4M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $19.3b | $112.75 | +5.8% | 2.2M |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $18.7b | $67.14 | +12.6% | 12.8M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $17.2b | $150.70 | +4.5% | 3.7M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $14.8b | $229.94 | +1.7% | 517.2K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $12.7b | $54.90 | +3.0% | 1.8M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $8.7b | $123.85 | -0.0% | 1.6M |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.9b | $75.08 | +3.2% | 1.7M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $7.9b | $8.48 | +11.6% | 23.1M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $7.5b | $86.66 | +3.1% | 616.3K |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | -0.0% | 16.1M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.5b | $99.14 | +4.2% | 1.2M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $109.25 | +0.6% | 899.0K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.0b | $38.20 | +0.0% | 3.1M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.5b | $72.01 | -1.3% | 1.4M |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.7b | $18.71 | -1.0% | 4.0M |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $4.6b | $118.06 | +5.1% | 896.9K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.0b | $16.05 | +6.9% | 7.7M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.7b | $60.50 | +3.3% | 1.1M |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.2b | $31.36 | +2.5% | 1.6M |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.2b | $30.50 | +4.3% | 6.0M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $3.1b | $65.97 | -1.1% | 401.6K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.1b | $18.67 | +3.9% | 4.0M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.6b | $35.44 | +1.2% | 1.7M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.5b | $50.07 | +2.0% | 3.3M |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.5b | $19.87 | +3.0% | 1.6M |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.4b | $21.02 | +3.4% | 2.7M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.2b | $63.62 | +2.4% | 1.1M |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.0b | $31.91 | +3.0% | 1.3M |
 NVCR | NovoCure Limited Ordinary Shares | Targeted Therapy & Precision Oncology | $2.0b | $15.31 | +2.7% | 877.1K |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $2.0b | $16.63 | +3.9% | 4.4M |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $1.9b | $7.40 | +10.7% | 13.6M |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $1.8b | $24.42 | +1.6% | 390.1K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.8b | $22.35 | +2.0% | 2.9M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.8b | $4.24 | +0.4% | 10.9M |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $1.7b | $21.15 | +7.6% | 2.0M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $1.7b | $12.21 | +17.7% | 15.4M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $22.23 | +2.9% | 1.6M |